NDC 58066-7014

Sore Throat and Laryngitis Response

Aconitum Napellus, Antimonium Crudum, Arum Triphyllum, Borax, Causticum, Ferrum Phosphoricum, Graphites, Hepar Sulphuris Calcareum, Kali Bichromicum, Lac Defloratum, Phosphorus, Selenium Metallicum, Spongia Tosta

Sore Throat and Laryngitis Response is a Oral Liquid in the Human Otc Drug category. It is labeled and distributed by Beaumont Bio Med. The primary component is Aconitum Napellus; Antimony Trisulfide; Arisaema Triphyllum Root; Sodium Borate; Causticum; Ferrosoferric Phosphate; Graphite; Calcium Sulfide; Potassium Dichromate; Skim Milk; Phosphorus; Selenium; Spongia Officinalis Skeleton, Roasted.

Product ID58066-7014_dc668798-dd9b-4af5-be07-3877c8462cc4
NDC58066-7014
Product TypeHuman Otc Drug
Proprietary NameSore Throat and Laryngitis Response
Generic NameAconitum Napellus, Antimonium Crudum, Arum Triphyllum, Borax, Causticum, Ferrum Phosphoricum, Graphites, Hepar Sulphuris Calcareum, Kali Bichromicum, Lac Defloratum, Phosphorus, Selenium Metallicum, Spongia Tosta
Dosage FormLiquid
Route of AdministrationORAL
Marketing Start Date2011-12-20
Marketing CategoryUNAPPROVED HOMEOPATHIC / UNAPPROVED HOMEOPATHIC
Labeler NameBeaumont Bio Med
Substance NameACONITUM NAPELLUS; ANTIMONY TRISULFIDE; ARISAEMA TRIPHYLLUM ROOT; SODIUM BORATE; CAUSTICUM; FERROSOFERRIC PHOSPHATE; GRAPHITE; CALCIUM SULFIDE; POTASSIUM DICHROMATE; SKIM MILK; PHOSPHORUS; SELENIUM; SPONGIA OFFICINALIS SKELETON, ROASTED
Active Ingredient Strength10 [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL; [hp_X]/59.2mL
NDC Exclude FlagN
Listing Certified Through2019-12-31

Packaging

NDC 58066-7014-7

59.2 mL in 1 BOTTLE, SPRAY (58066-7014-7)
Marketing Start Date2011-12-20
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 58066-7014-7 [58066701407]

Sore Throat and Laryngitis Response LIQUID
Marketing Categoryunapproved homeopathic
Product TypeHUMAN OTC DRUG
Marketing Start Date2011-12-20
Inactivation Date2020-01-31

Drug Details


© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.